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Abstract: The current method for Babesia spp. serodiagnosis based on a crude merozoite antigen is
a complex and time-consuming procedure. An indirect enzyme-linked immunosorbent assay (iELISA)
based on a recombinant multi-antigen of Babesia bovis (rMABbO) was developed for detection of
antibodies in bovines suspected of infection with this parasite. The multi-antigen comprises gene
fragments of three previously characterized B. bovis antigens: MSA-2c, RAP-1 and the Heat Shock
protein 20 that are well-conserved among geographically distant strains. The cutoff value for the new
rMABbo-iELISA was determined using 75 known—positive and 300 known—negative bovine sera
previously tested for antibodies to B. bovis by the gold-standard ELISA which uses a merozoite lysate.
A cutoff value of ≥35% was determined in these samples by receiver operator characteristic (ROC)
curve analysis, showing a sensitivity of 95.9% and a specificity of 94.3%. The rMABbo-iELISA was
further tested in a blind trial using an additional set of 263 field bovine sera from enzootic and tick-free
regions of Argentina. Results showed a good agreement with the gold standard test with a Cohen’s
kappa value of 0.76. Finally, the prevalence of bovine babesiosis in different tick enzootic regions
of Argentina was analyzed where seropositivity values among 68–80% were obtained. A certain
level of cross reaction was observed when samples from B. bigemina infected cattle were analyzed
with the new test, which can be attributed to shared epitopes between 2 of the 3 antigens. This new
rMABbo-iELISA could be considered a simpler alternative to detect anti Babesia spp. antibodies and
appears to be well suited to perform epidemiological surveys at the herd level in regions where ticks
are present.
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1. Introduction
The intraerythrocytic protozoan parasites Babesia bovis and B. bigemina are the main causative
agents of bovine babesiosis. The disease is widespread in tropical and sub-tropical regions of the
world where the main tick vector Rhipicephalus (Boophilus) microplus is present [1]. In Argentina,
the economical losses in the livestock industry due to treatments and prevention of babesiosis exceed
US$38 million per year [2]. All babesial parasites may cause anemia, but B. bovis infection causes
a severe disease characterized by hemolytic anemia, neurological and kidney damage, respiratory
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shock and high mortality in adult bovines [3]. A live attenuated vaccine against bovine babesiosis
is commercially available in many countries and is currently used. This vaccine can be used safely
only in calves under 12 months of age living in enzootically unstable areas [4]. The vaccine is usually
administered as a bivalent formula with each B. bovis and B. bigemina attenuated strains.
In order to attain enzootic stability to Babesia spp., at least 75% of the herd should have been bitten
at early ages by infected ticks and develop serum antibodies against both Babesia species [5]. In this
context, the main application of serological tests is to determine the presence of anti-Babesia antibodies
generated after natural infection of calves or after vaccination. Among the most common tests are
the indirect fluorescent antibody test (IFAT) and enzyme-linked immunosorbent assays (ELISA).
Competitive ELISA tests were developed for detecting antibodies against both Babesia species [6,7]
and indirect ELISAs have also been developed using different recombinant antigens [8,9]. All these
tests have shown variable results but none of them is available in the market at this time. For this
reason, these developments have not replaced the use of an iELISA based on a crude merozoite lysate
(MZ-iELISA). This method relies on the maintenance of in vitro Babesia cell cultures and purification of
merozoites, a complex and time-demanding procedure.
In this work we evaluated the performance of an iELISA using a novel chimerical multi-antigen
previously developed in our laboratory [10]. This recombinant multi-antigen (rMABbo) was developed
as a vaccine candidate and comprises gene fragments with B and T cell epitopes of three B. bovis
antigens: MSA-2c, RAP-1 and the Heat Shock protein 20. Unexpectedly, we found that the rMABbo
was recognized by antibodies present in bovines naturally infected with different B. bovis isolates,
suggesting a potential usefulness of this chimeric protein as a serological tool. The aim of this study
was to evaluate the performance of the rMABbo in an iELISA format as a simple and rapid alternative
to detect Babesia antibodies in cattle.
2. Materials and Methods
2.1. Expression and Purification of the Recombinant Multi-Antigen of B. bovis, rMABbo
In order to obtain the rMABbo, the fragments of msa-2c, rap-1 and hsp20 (GenBank AY052542.1,
AF030062.1, and AF331455.1, respectively) were firstly amplified by PCR and sequentially ligated
into a pCR®8/GW-TOPO®TA Gateway cloning kit vector (Invitrogen Corp, Carlsbad, CA, USA).
Then, the single genetic sequence encoding the rMABbo was transferred directionally into pDEST 17™
vector and expressed in E. coli strain BL21 AI™ (both from Invitrogen) as previously described [10].
The rMABbo contains a 6X Histidine tag and was purified under denaturing conditions with
a Ni-Agarose resin (Probond, Invitrogen) according to the manufacturer’s instructions. Total protein
was quantified with a BCA commercial kit (Pierce, Rockford, IL, USA) and stored in aliquots at −20 ◦C
until used.
2.2. Origin of Serum Samples, Study Sites and Ethics Statement
For the calculation of the cutoff value, the receiver operator characteristic (ROC) analysis was
used with a set of known—positive and known—negative sera. The known—positive sera (n = 75)
were from B. bovis experimentally-infected bovines inoculated with 107 infected erythrocytes of the
R1A attenuated strain.
Cattle used for this experimental infection were 10-months-old Bos taurus mixed breed, which were
tested previously by the MZ-iELISA [11] for the absence of anti B. bovis antibodies before use.
Forty- five days after inoculation, all serum samples were confirmed positive by the MZ-iELISA
and were the samples used in this study. The known—negative serum samples (n = 300) used here
were from up to 6-month-old Jersey/Holstein crossbred calves born and raised in a dairy farm located
in Tandil [12] located in the Buenos Aires province of Argentina. This province is below parallel 30◦ S,
a tick-free area of the country. These sera were also negative for the MZ-iELISA.
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For the seroprevalence analysis, only the rMABbo-iELISA was used. Samples were from bovines
from the Argentinean provinces of Corrientes (n = 89) and Misiones (n = 67) which are both above
parallel 30◦ S and enzootic for the Rhipicephalus microplus tick. Animals were Angus/Brangus crossbred
and had never been vaccinated with the bivalent live vaccine against bovine babesiosis.
An additional set of serum samples was used in a blind test to estimate concordance by the
Cohen’s kappa value. For this, a total of 263 sera were evaluated separately by both rMABbo-iELISA
and MZ-iELISA as the gold standard. These samples were obtained from bovines from the provinces
of Corrientes (n = 115) and Misiones (n = 67). Both provinces are above parallel 30◦ S where ticks are
enzootic. Eighty-one sera cattle from Tandil region (n = 81) were also included to test specificity, a set
of B. bigemina (n = 47) and Anaplasma marginale (n = 5) serologically positive sera were used. All these
sera were tested negative for B. bovis antibodies by the current MZ-iELISA.
All the serum samples used in this work were obtained by cattle manually restrained (<5 min)
and blood samples were aseptically collected by jugular venipuncture (Vacutainer™, Becton Dickinson,
Franklin Lakes, NJ, USA, <0.0005% blood volume; one sampling per animal).
The protocol for animal handling and venipuncture was performed following the guidelines of
the Institutional Committee for the Use and Care of Experimentation Animals (protocol approval
No. 025/2011). All samples came from privately owned herds and were sampled with the approval of
the owners.
2.3. Pre-Adsorption of Serum Samples
Cattle sera were incubated at 37 ◦C for 2 h in pre-adsorption solution to avoid unspecific binding
of bovine antibodies [13]. The solution was 5% (w/v) non-fat dried milk and 100 µg/mL of bacterial
culture lysate supernatant in 0.5% (v/v)-solution of Tween 20 in 1× PBS. Briefly, the bacterial lysate
was obtained from 50 mL of overnight Escherichia coli culture of strain BL21 AI™ (Invitrogen). Then,
the culture was harvested and centrifuged at 17,257 g during 10 min at 4 ◦C. The supernatant was
discarded and the pellet resuspended with gentle agitation for 2 h at 4 ◦C in 4 mL of lysis buffer
(100 mM Tris HCl, pH: 7.5; 500 mM NaCl; 20% glycerol; 1% Triton X-100; 20 mM imidazole (pH: 7.4);
plus 1 mg/mL Lysozyme and 0.5 mM phenylmethylsulfonyl fluoride). The suspension was sonicated
by three cycles (1 min/cycle) and centrifuged at 14,501 g during 30 min at 4 ◦C. The supernatant was
separated from the pellet and used. Total protein was quantified with a BCA commercial kit (Pierce,
Rockford, IL, USA) and stored at −20 ◦C until used.
2.4. Indirect ELISA Procedure
The MZ-iELISA was performed as described by de Echaide et al., 1995. This technique has been
validated by the OIE—World organization for Animal Health as a gold standard method for serological
diagnosis. For the rMABbo-iELISA a standard protocol was set up. Different concentrations of antigen
(10, 20, 30 and 40 ng) and serum dilutions (1:10, 1:20, 1:50 and 1:100) were previously checked in
triplicates in order to optimize the assay conditions (data not shown). Immulon 2 HB Flat Bottom
Micro Titer plates (Nunc) were coated overnight at 4 ◦C with purified rMABbo (20 ng/well) in coating
buffer (15 mM Na2CO3, 35 mM NaHCO3, 0.05% Na-azide, (pH: 9.6). The plates were blocked for 1 h
at 37 ◦C with 100 µL of the pre-adsorption solution.
Pre-adsorbed serum samples (1:50 dilution) were added after 3 washes with 0.05% Tween—20 in
1× PBS and the plates were incubated for 1 h at 37 ◦C. The plates were washed again with 0.05%
Tween—20 1× PBS and incubated with horseradish peroxidase-conjugated goat anti-bovine IgG
(Sigma-Aldrich, Saint Louis, MI, USA) for 1 h at 37 ◦C. The reaction was developed by the addition of
100 µL/well of OptEIA™ TMB Substrate Reagent Set (Pharmigen) and stopped after 20–30 min with
50 µL/well of H2SO4 2N solution. The absorbance was measured with a Multiskan spectrophotometer
at a wavelength of 450 nm (Labsystems, Basingtoke Hants, UK). Three strong positive samples,
previously tested by the MZ-iELISA were included in each plate as reference controls and used as
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duplicates. Additionally, three negative sera reference from a free-tick region were also included as
duplicates in each plate.
In all cases, the absorbance (A) of each serum was expressed as positivity percentage (% P)
of th mean value of the positive controls according to the following formula = [(A450nm of serum
sample × 100)/Average of A450nm of positive control sera].
2.5. Data Analysis
The cutoff point for rMABbo-iELISA was established with the ROC curve (95% confidence interval)
using MedCalc Statistical Software version 15.4 (MedCalc Software bvba, Ostend, Belgium; https://
www.medcalc.org; 2015). This method allows the estimation of the diagnostic specificity and sensitivity
of an established diagnostic method. A frequency distribution graph was also plotted with this
program. Concordance between the current ELISA based on B. bovis merozoite and rMABbo-iELISA
was estimated by Cohen’s kappa value, k, as previously described [14].
3. Results
Purification of the E. coli recombinant multi-antigen by Ni-agarose chromatography gave a high
purification yield. The purified protein was obtained as a clear band corresponding to the expected
molecular weight of 72 kDa in a concentration of 1.2 mg/mL (Figure 1).
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Figure 1. A 12% SDS-PAGE a alysis showing the expression and purification of recombinant B. bovis
multi-antigen, rMABbo. M: olecular weight marker (Promega). Lane 1: uninduced control; lane 2:
level of expression 4 h post-induction with 0, 2% Arabinose; lane 3: purified rMABbo after elution with
250 mM Imidazole.
To evaluate whether the rMABbo can be a suitable antigen for the diagnosis of a B. bovis infection,
the purified protein was initially tested using samples of known serological status. As shown in
Figure 2A, using 300 negative sera from tick-free areas and 75 samples from B. bovis experimentally
infected bovines, the ROC analysis showed an area under the curve, AUC, of 0.995 which means
an excellent capability to discriminate truly infected from truly uninfected animals.
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Figure 2. ROC analysis for the rMABbo-iELISA. (A) Interactive dot plot of the frequency distribution
based on 300 known negative sera from tick-free regions of Argentina and 75 known positive sera from
experimentally B. bovis infected bovines with the attenuated R1A strain. The horizontal line shows the
cutoff value of ≥35%, providing a sensitivity of 95.9% and a specificity of 94.3% (B). Sensitivity and
100—Specificity values are plotted on the y-axis and x-axis, respectively. Red thick line indicates the
fitted ROC curve and thin blue lines indicate the 95% confidence interval of the fitted ROC curve.
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The frequency distribution plot of both negative and positive known sera is shown in Figure 2B.
With the ROC analysis and establishing a priori a sensitivity of 95.9% and a specificity of 94.3%, a cutoff
value of≥35% was established. With these values only 2 false-negative and 18 false-positive test results
were obtained out of the 375 samples analyzed.
In a further step, we evaluated the concordance between rMABbo-iELISA and the MZ-iELISA
using a panel of an additional set of 263 bovine sera collected from tick and tick free areas of Argentina.
The level of agreement was determined using the Cohen’s k value (Table 1). The cross-tabulation
between these two tests showed a good level of agreement, resulting in k = 0.76 (0.6 < k ≤ 0.8;
good agreement). Thus, a total of 232 out of 263 sera (85.5%) tested either positive (n = 140) or negative
(n = 92) by both iELISAs, while only 31 samples (11.8%) were discrepant. Twenty-nine of these samples
(11%) were only positive for MZ-iELISA whilst only two samples (0.8%) resulted positive for the
rMABbo-iELISA being negative for the MZ-iELISA (Table 1).
Table 1. rMABbo-iELISA and MZ-iELISA blind test on bovine sera from Argentina. A total of
263 samples were used, 182 of them are originated from endemic areas and 81 from tick-free areas
where the vector is not widespread.
MZ-iELISA
rMABbo-iELISA + − Total
+ 140 2 142
− 29 92 121
Total 169 94 263
With the cutoff value of ≥35%, the overall data obtained with this new rMABbo-iELISA showed
a high seroprevalence in both Corrientes and Misiones provinces where R. microplus is present (Table 2).
In Corrientes province, the seroprevalence reached values above 80%, whereas in Misiones the values
were close to 70%.
Table 2. rMABbo-iELISA serological results of serum samples originated from areas where B. bovis
is endemic.
Origin of the Sera Positive Negative Total % Prevalence
Misiones 46 22 68 67
Corrientes 98 17 115 85
Regarding species specificity, the rMABbo-iELISA was tested with samples originated from
regions where the tick R. microplus is present and may also transmit other hemoparasites to bovines
(i.e., B. bigemina and Anaplasma marginale).
All the A. marginale positive sera (n = 5) scored below the cutoff established value and were
considered negative. However, of a total of 47 samples serologically positive by the standard iELISA
to B. bigemina, 33 showed cross-reactivity with the rMABbo protein with a variable percentage of
positivity above the cutoff value (between 40% and 80% of positivity).
4. Discussion and Conclusions
The serodiagnosis of bovine babesiosis is one of the approaches to control and prevent the
dissemination of the disease. At present, there are no commercial ELISA kits for diagnosis of bovine
babesiosis caused by either B. bovis or B. bigemina. In Argentina, the only validated iELISA employs
a crude merozoite lysate as the detection antigen. Even though these MZ-iELISA show optimum values
of specificity and sensitivity the production of native parasite antigen is difficult, time-consuming and
involves maintenance of merozoites in donor bovine red blood cells.
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In this work, we have developed an iELISA based on a chimeric polyprotein comprising the
immunodominant regions of three B. bovis antigens, optimizing the display of multiple B cell epitopes
in only one protein. In our previous work, we had observed that all samples of a small group of sera
from B. bovis naturally-infected bovines recognized the rMABbo in western blots, whereas sera from
non-infected cattle did not react [10]. These results led us to move a step further and assay this protein
as a detection antigen in an iELISA format.
A common problem observed in diagnosis with indirect ELISAs based on recombinant proteins
expressed in prokaryotic systems is the contamination of bacterial proteins with the recombinant
antigen, to which bovine serum reacts strongly affecting the interpretation of the results [15].
To overcome this possible drawback we have added an additional blocking mixture of a bacterial
lysate to avoid unspecific binding [13]. In our hands, the rMABbo-iELISA showed a low background
of unspecific signal and only a few number of truly negative sera resulted as false positive (18 out of
300 samples).
ROC analysis was applied to the rMABbo-iELISA to assess the cutoff value using a batch of
samples of known serological status. The cutoff value of 35% obtained in our study is similar to the
value obtained by other studies using iELISA based on recombinant antigens and bovine sera [16,17].
Sensitivity and specificity of the rMABbo-iELISA was optimal and very similar to the values reported
for the MZ-iELISA [15].
Finally, the concordance of rMABbo-iELISA with the MZ-iELISA in a blind trial test was
performed using a panel of an additional set of 263 bovine sera collected in the field from enzootic and
non-enzootic areas of Argentina. Although the Cohen’s kappa value between both iELISAs showed
a good level of agreement, for a definitive validation, a larger number of samples should be tested to
achieve more conclusive results.
Regarding species-specificity, the rMABbo-ELISA showed cross-reactivity with sera from B. bigemina—
infected cattle. Since the rMABbo includes an N-terminal fragment of RAP-1 (amino acids 22 to 236)
with 45% of amino acid identity to B. bigemina RAP-1, this cross-reaction could be explained by common
B cell epitopes between both Babesia species. Similar results were obtained by Suarez et al. (1991) when
using RAP-1 from B. bovis and sera from B. bigemina-infected animals [18].
There is also a high amino acid sequence identity (90%) between HSP20 proteins of both Babesia
species [19], which could also account for the cross-reaction observed in the heterologous sera tested.
This lack of species-specificity due to sequence conservation among antigens chosen for diagnostic
purposes is not unusual when recombinant proteins of other parasitic protozoa were used for
diagnosis of different species of the same genus. Previous studies of an iELISA for diagnosis of
bovine trypanosomosis, showed different level of cross-reactivity when recombinant antigens were
used [20]. In addition, a recombinant tandem repeat antigen used in an iELISA for detecting
antibodies against surra in water buffaloes, showed cross-reactivity between Trypanosoma theileri
and T. evansi [13]. Another iELISA based on a recombinant antigen against Theileria spp. showed
cross-reactivity between T. uilenbergi and T. Luwenshuni in small ruminants [16]. Additionally, in a recent
report of an indirect ELISA for the detection of bovine Theileria based on three immunodominant
proteins, the authors reported a strong cross-reactivity showed in cattle infected with T. annulata,
T. orientalis and T. sinensis [17]. Overall, these findings represent one of the major challenges for the
selection of immunodominant antigens for diagnostic purposes.
Even though this lack of species-specificity of the rMABbo-iELISA would mean a limitation
for the species-specific diagnosis, it must be reminded that detection of either Babesia species would
require the same intervention at the herd level since there is no difference in the chemotherapeutic
treatment of ill animals or management of the tick vector [4]. In this context, our iELISA could
be a useful tool for studying the epidemiological status of cattle herds at a regional scale in order
to make a prompt decision such as immunization, animal re-location or application of acaricides.
In conclusion, the rMABbo-iELISA appears well suited to perform epidemiological surveys like our
study in two different regions of Argentina where no previous infection rates are recorded. This would
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give an overview of the prevalence of the disease and to assess the economic impact in areas where
infection with Babesia spp. is enzootic.
5. Patent
José Manuel Jaramillo Ortiz and Silvina Elizabeth Wilkowsky are named inventors on patent
application “Chimeric polypeptide, vaccine against babesiosis, immunization methods, detection
methods and kit” WO 2016209859 A1.
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